From: NASA HQ
Posted: Wednesday, September 12, 2007
I. PURPOSE AND SCOPE
This Memorandum of Understanding (MOU) sets forth a framework of cooperation between the National Institutes of Health (NIH) and the National Aeronautics and Space Administration (NASA) to encourage:
Of particular interest is the application of the United States (U.S.) portion of the International Space Station (ISS) as a national laboratory, as established by P.L. 109-155. The designation as a National Laboratory underscores the significance and importance that the U.S. places on the scientific potential of the ISS for research in areas including, but not limited to:
Each agency has existing programs and resources for facilitating health research and technology development. Research facilitated by this MOU will be complementary to studies supported by the NIH, its Institutes and Centers, and NASA, at the agencies' intramural or extramural laboratories. In pursuing objectives through this MOU, the NIH and NASA shall handle their own activities and use their own resources, including the expenditure of their own funds unless otherwise agreed in specific implementing agreements.
The NIH enters into this MOU in accordance with section 301 of the Public Health Service Act, which authorizes NIH to cooperate with public authorities and scientific institutions. The NASA enters into this MOU, pursuant to section 203(c) of the National Aeronautics and Space Act of 1958, as amended [42 U.S.C. 2473 (c)].
The NIH and NASA may be individually referred to as a "Party" and collectively referred to as the "Parties." Nothing in this MOU alters the statutory authorities of the NIH or NASA. It is intended to facilitate cooperative efforts for mutual provision of services and support, as well as technical assistance by both agencies in the conduct of research and development of technologies in the area of space-related health research. It does not supersede or void existing agreements between NASA and the NIH or any of its Institutes or Centers.
The programmatic strengths of the NIH and NASA offer opportunities for synergy that can accelerate basic knowledge and technology development that can be applied to humans in space and on Earth. For example, NASA enables research in reduced gravity by facilitating access to the unique environment of space and has created systems that are analogous to the space environment. NASA also supports technologies that are not yet available to Earth-based researchers that could contribute greatly to biomedical advances pursued by NIH-funded investigators. Likewise, the NIH, with its 27 Institutes and Centers, is capable of reaching a broad range of basic and clinical biomedical researchers whose involvement in space-related projects would create an intellectual environment where unanticipated breakthroughs could occur.
In a report accompanying the NASA Authorization Act of 2005 (P.L. 109-155), the Senate Committee on Commerce, Science, and Transportation repeatedly emphasized that a primary justification for support of the ISS is its scientific and research potential (Senate Report 109-108). Recognizing that the ISS will be capable of hosting a wide range of scientific research that can only be undertaken in a microgravity environment, the authors of P.L. 109-155 specifically noted that the NASA portfolio should include microgravity research that is not related directly to its human exploration efforts (e.g., growth of molecular crystals, development of cell-based technologies).
When complete, the ISS will provide a unique life sciences laboratory and will be able to facilitate testing of new biosensors and telemedicine technologies. It also may promote development of international research collaborations that would improve the lives of people around the world or accelerate fundamental discoveries. The U.S. segment of the ISS will have laboratory space, data processing capabilities, and crew time for experiments conducted on the ISS once it is fully operational in 2011. Because commitment of ISS resources is likely to be made on a first come, first serve basis through strategic alliances that will advance research in biomedicine and biotechnology, now is an appropriate time for researchers supported by the NIH to begin proposing studies, conducting preliminary experiments on Earth, and arranging with NASA to have their hypotheses tested on the ISS after its assembly has been completed.
This MOU is intended to provide an enabling mechanism for coordination and cooperation whenever appropriate and mutually beneficial, subject to program priorities and budget constraints. Within the context of the Purpose and Scope above, the NIH agrees to use reasonable efforts to:
Within the context of the purpose and scope above, the NIH and NASA agree to use reasonable efforts to:
V. RESPONSIBLE OFFICERS /AGENCY CONTACTS
For the National Institutes of Health:
Anita M. Linde
Director, Office of Science Policy and Planning
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Building 31, Room 4C13
National Institutes of Health
Bethesda, MD 20892-2350
For the National Aeronautics and Space Administration:
Assistant Associate Administrator
International Space Station
Space Operations Mission Directorate, Suite 7P39
National Aeronautics and Space Administration
Washington, DC 20546-0001
VI. FINANCIAL OBLIGATIONS
There will be no transfer of funds or other financial obligations between NASA and NIH under this Agreement. Each Party will fund its own participation. All activities under or pursuant to this agreement are subject to the availability of appropriated funds, and no provision herein shall be interpreted to require obligations or payment of funds in violation of the Anti-Deficiency Act, 31 U.S.C. S 1341.
VII. DATA RIGHTS
The Parties agree that the information and data exchanged in furtherance of the activities under this MOU will be exchanged without use and disclosure restrictions unless required by national security regulations or otherwise agreed to by the Parties for specifically identified information or data (e.g., information or data specifically marked with a restrictive notice).
VIII. AMENDMENT AND TERMINATION
The MOU may be amended at any time by the mutual written consent of the Agencies. On an annual basis, the Parties will conduct a review of this MOU to evaluate progress and achievement of mutual goals and objectives consistent with the purpose and scope. Either Party may unilaterally terminate this MOU by providing 90 calendar days written notice to the other Party.
IX. TERM OF AGREEMENT
This MOU will be effective upon the date of the last signature below, and shall remain in effect for 5 years. At the conclusion of 5 years, the parties will consider the development of a new agreement.
X. ACCEPTANCE AND APPROVAL OF AUTHORIZING OFFICIALS
Elias A. Zerhouni, M.D. Date Director, National Institute of Health
Michael D. Griffin Date NASA Administrator
// end //